IRIS
MARTORA, FABRIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.277
EU - Europa 2.280
NA - Nord America 1.943
SA - Sud America 533
AF - Africa 74
OC - Oceania 4
Totale 9.111
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.832
SG - Singapore 1.811
CN - Cina 1.102
RU - Federazione Russa 1.076
DE - Germania 573
VN - Vietnam 482
BR - Brasile 443
HK - Hong Kong 256
IT - Italia 218
IN - India 188
KR - Corea 130
FR - Francia 103
FI - Finlandia 92
BD - Bangladesh 85
JP - Giappone 79
GB - Regno Unito 48
AR - Argentina 45
NL - Olanda 45
CA - Canada 44
MX - Messico 39
ES - Italia 26
IQ - Iraq 25
ZA - Sudafrica 22
UA - Ucraina 20
ID - Indonesia 16
PK - Pakistan 16
AT - Austria 15
EC - Ecuador 15
PH - Filippine 15
PL - Polonia 13
IE - Irlanda 11
TH - Thailandia 11
KE - Kenya 10
MA - Marocco 9
TR - Turchia 9
CI - Costa d'Avorio 7
TW - Taiwan 7
VE - Venezuela 7
CL - Cile 6
DZ - Algeria 6
IL - Israele 6
LT - Lituania 6
OM - Oman 6
RS - Serbia 6
EG - Egitto 5
SE - Svezia 5
UY - Uruguay 5
CR - Costa Rica 4
DO - Repubblica Dominicana 4
JO - Giordania 4
PY - Paraguay 4
BO - Bolivia 3
CO - Colombia 3
EE - Estonia 3
KZ - Kazakistan 3
NI - Nicaragua 3
PA - Panama 3
RO - Romania 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AF - Afghanistan, Repubblica islamica di 2
AL - Albania 2
AZ - Azerbaigian 2
BY - Bielorussia 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
GH - Ghana 2
GN - Guinea 2
JM - Giamaica 2
KH - Cambogia 2
KW - Kuwait 2
MR - Mauritania 2
MY - Malesia 2
PE - Perù 2
PR - Porto Rico 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
AM - Armenia 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BE - Belgio 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BW - Botswana 1
CH - Svizzera 1
CV - Capo Verde 1
ET - Etiopia 1
GM - Gambi 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HT - Haiti 1
KG - Kirghizistan 1
LB - Libano 1
LC - Santa Lucia 1
Totale 9.099
Salva come PNG Salva come JPEG
Città #
Singapore 971
Hefei 614
San Jose 472
Moscow 282
Hong Kong 246
Santa Clara 215
Ashburn 187
Beijing 169
Ho Chi Minh City 147
Kochi 131
Munich 128
Seoul 122
Hanoi 113
Krefeld 113
Lauterbourg 78
The Dalles 73
Tokyo 71
Los Angeles 70
Helsinki 53
Bad Bellingen 50
São Paulo 47
Naples 42
New York 42
Dallas 39
Redondo Beach 38
Buffalo 28
Da Nang 21
Council Bluffs 20
Lappeenranta 20
Milan 20
Chicago 18
Mexico City 18
Rome 18
Seattle 18
Orem 17
Boston 16
Haiphong 16
Brooklyn 15
Chennai 14
Nuremberg 14
Rio de Janeiro 13
Boardman 12
Toronto 12
Dublin 11
Frankfurt am Main 11
London 11
Atlanta 10
Baghdad 10
Belo Horizonte 10
Biên Hòa 10
Denver 10
Turku 10
Curitiba 9
Houston 9
Poplar 9
Falkenstein 8
Montreal 8
Nairobi 8
Warsaw 8
Amsterdam 7
Brasília 7
Campinas 7
Florence 7
Kronberg 7
Phoenix 7
Salvador 7
Xi'an 7
Bắc Giang 6
Guayaquil 6
Johannesburg 6
Jyväskylä 6
Lahore 6
Paris 6
Porto Alegre 6
Pune 6
Ribeirão Preto 6
Rochdale 6
Turin 6
Vienna 6
Ankara 5
Can Tho 5
Ha Long 5
Hải Dương 5
Manchester 5
Montevideo 5
Mumbai 5
New Delhi 5
Salt Lake City 5
San Francisco 5
Santo André 5
Shanghai 5
Zhengzhou 5
Amman 4
Bengaluru 4
Buenos Aires 4
Cape Town 4
Dhaka 4
Don Benito 4
Düsseldorf 4
Erbil 4
Totale 5.200
Salva come PNG Salva come JPEG
Nome #
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study 394
Effect of Dupilumab on Sexual Desire in Adult Patients with Moderate to Severe Atopic Dermatitis 283
Comprehensive Molecular Analysis of Disease-Related Genes as First-Tier Test for Early Diagnosis, Classification, and Management of Patients Affected by Nonsyndromic Ichthyosis 166
Effectiveness and Safety of Upadacitinib for Adolescents with Atopic Dermatitis in a Real-World Setting 139
Management of Psoriasis Patients with Serious Infectious Diseases 137
Tattooing and hidradenitis suppurativa: stigmatization and camouflage 135
Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience 133
Comment on ‘Anogenital dermatology: challenges in the digital era’ 131
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients 130
The use of ChatGPT in the dermatological field: a narrative review 129
Letter to the editor regarding article "Falotico JM, Gu L, Lipner SR. Not just pimple popping: The utility of hybrid telemedicine models beyond acne management amidst the ongoing COVID-19 pandemic. J Cosmet Dermatol. 2022;10.1111/jocd.15256" 128
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients 128
Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study 128
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review 126
Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature 125
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature 123
The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review 119
Risk Factors for Psoriasis Flares: A Narrative Review 118
Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis 116
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection 116
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature 114
Efficacy and Safety of Cemiplimab for the Management of Non-Melanoma Skin Cancer: A Drug Safety Evaluation 112
Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19 111
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation 111
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis 111
Oral Minoxidil for Chemotherapy-Induced Alopecia 110
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials 109
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study 109
Lichen planus following Covid-19 vaccination: a narrative review 108
Unaddressed Challenges in the Treatment of Cutaneous Melanoma? 108
How Adalimumab Impacts Antibiotic Prescriptions in Patients Affected by Hidradenitis Suppurativa: A 1-Year Prospective Study and Retrospective Analysis 107
Airborne allergic contact dermatitis "by proxy" due to budesonide 107
Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study 107
Hidradenitis Suppurativa Cancer Risk: A Review of the Literature 106
Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a psoriasis patient. Comment on "Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab" 105
Dietary intervention in acne management: review of the literature and future prospective 104
Comment on ‘Pityriasis rubra pilaris-like eruption following mRNA COVID-19 vaccine’ 104
Very low-calorie ketogenic diet (VLCKD) in the management of hidradenitis suppurativa (Acne Inversa): an effective and safe tool for improvement of the clinical severity of disease. Results of a pilot study 104
Efficacy and Safety of bimekizumab in psoriasis management in real-life: bio-naïve vs bio-experienced 103
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge 103
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review 102
Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities 102
Comment on ‘Permethrin-unresponsive scabies in London, UK: a wake-up call’ 101
Guselkumab-induced vitiligo in a patient with psoriatic arthritis 100
Comment on: “Clinical characteristics of patients with pityriasis rubra pilaris following SARS‐CoV‐2 vaccination” by Gambichler 100
Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future? 99
Reply to 'Omalizumab for the management of refractory aquagenic pruritus' 99
The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature 98
Comment on: "Associations between hidradenitis suppurativa and dermatological conditions in adults: A national cross-sectional study by Brown et al." 97
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab 97
Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation 96
Climate change and the role of dermatologists: a call to action 93
The role of teledermatology for the long-term management of stable psoriasis treated with biologics: a survey-based study 91
Effectiveness, Safety, and Long-Term Continuation Rate Analysis of Dupilumab Treatment in Adolescents with Atopic Dermatitis: A Single-Center Real-Life Retrospective Study 91
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation 90
The Past, the Present and the Future of Teledermatology: A Narrative Review 90
Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review 87
Reply to Borgia et al. Comment on “Marasca et al. Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. J. Clin. Med. 2022, 11, 1511” 85
Hidradenitis Suppurativa in Elderly Patients: Clinical and Therapeutical Outcomes—A Review of the Literature 85
Reply to ‘Effectiveness, safety and drug survival of oral roflumilast for hidradenitis suppurativa’ by Holgersen et al 84
Comment on 'Development of Chilblains Lesions During the COVID-19 Pandemic is Strongly Associated with Cold Weather: Retrospective Analysis of Patients from a Single Center in the United States' 83
Author Reply to “Comment on ChatGPT and Medical Writing in Dermatology: why should we keep writing?” by Daungsupawong et al 81
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report 81
Herpes Zoster and COVID-19 Vaccination: A Narrative Review 80
Viral Reactivation Following COVID-19 Vaccination: a review of the current literature 79
Comment on “Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review” 78
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data 78
An update on the current and emerging pharmacotherapies for basal cell carcinomas 77
Author Reply to “Comment on ChatGPT and Medical Writing in Dermatology: why should we keep writing?” by Duff et al 75
ChatGPT and dermatology 73
ChatGPT and Dermatology: friends or foes? 72
Reply to “Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa” 72
Injection site reactions after dupilumab or tralokinumab for atopic dermatitis 70
L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter] 68
Reply to “Dalbavancin for the treatment of severe hidradenitis suppurativa” 66
Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study 65
Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration – A Case Report 63
Management of Advanced Invasive Melanoma: New Strategies 62
Allergic contact dermatitis to petrolatum: An unknown for patch testing 61
Comment on ‘Eosinophilic pustular folliculitis developing at the site of COVID-19 vaccination’ 61
Hypergammaglobulinemia in Hidradenitis Suppurativa Patients: A New Emerging Association 60
Advancing Dermatology: Embracing the Power of Artificial Intelligence 60
Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments 58
ChatGPT and Medical Writing in Dermatology: why should we keep writing? 56
Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective study 55
Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study 54
Severe Paradoxical Scalp Psoriasis Induced by Bimekizumab in a Young Multifailure Hidradenitis Suppurativa Patient 51
Comment on ‘Onset of epidermolysis bullosa acquisita under therapy with ustekinumab for the treatment of Crohn disease’ 51
Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era? 51
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review 51
Comment on ‘Oral ivermectin to treat scabies: a comparison of two different regimens’ 47
Guselkumab In A Subset Of Multifailure Patients With Hidradenitis Suppurativa: Real-Word Evidence from Federico II 43
Hidradenitis suppurativa and bimekizumab: Looking to the future 31
Reply to 'Rifampicin and clindamycin for epidermal growth factor receptor inhibitor-related acneiform rash' 23
Bimekizumab for Hidradenitis Suppurativa from Trials to Real Life: A Review of the Published Literature 22
Long-Term Outcomes of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: A Multicentre Cohort Study 14
Reply to ‘Real‐world experience of switching from tralokinumab to lebrikizumab in atopic dermatitis’ 11
Hidradenitis Suppurativa and IL-17 Inhibitors: A Focus on Trials and Real-Life Data 2
Totale 9.229
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.081
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.081
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202383 0 0 0 0 0 10 11 17 3 16 17 9
2023/2024720 13 22 50 18 11 24 16 42 331 40 77 76
2024/20252.993 104 158 35 31 79 237 288 243 201 398 998 221
2025/20265.433 576 873 637 610 729 200 459 362 471 271 203 42
Totale 9.229